Lv3
288 积分 2025-04-23 加入
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
2个月前
已完结
Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial
3个月前
已完结
INI1-Deficient Tumors
5个月前
已完结
Epidemiology of Sinonasal Cancer
5个月前
已完结
Mitochondrial pyruvate dehydrogenase kinase 1 drives bevacizumab resistance and malignant phenotype of TNBC by enhancing mitophagy
6个月前
已完结
SMARCB1 (Integrase Interactor 1)–Deficient Sinonasal Carcinoma of the Maxillary Sinus: A Newly Described Sinonasal Neoplasm
6个月前
已完结
Metastatic <b><i>SMARCB1</i></b> (<b><i>INI-1</i></b>)-Deficient Sinonasal Carcinoma Diagnosed by Endobronchial Ultrasound-Guided Fine-Needle Aspiration (EBUS-FNA): A Potential Diagnostic Pitfall and Review of the Literature
6个月前
已完结
SMARCB1 (INI1)-deficient sinonasal clear cell carcinoma: A new histological variant
6个月前
已关闭
SMARCB1/INI-1 deficient sinonasal carcinoma: An emerging entity
6个月前
已完结
Impact of Clinical Factors and Treatments on SMARCB1 (INI‐1)‐Deficient Sinonasal Carcinoma
6个月前
已完结
皖公网安备34019202002308
